Thyroid Function and the GH Axis: Why Peptide Protocols Depend on Adequate Thyroid Hormone

Thyroid hormone and growth hormone signalling are tightly interdependent, and an untreated thyroid imbalance can blunt or distort the response to GH-axis peptides. This article explains the physiology, what a thyroid panel should include, and how prescribers sequence thyroid optimisation before starting a protocol.

By UAE Peptide Clinic Research Desk

Growth hormone secretagogues such as ipamorelin, CJC-1295 and tesamorelin are among the most frequently prescribed peptides in the UAE, and the majority of patients who start them are thinking about the GH axis in isolation. In practice, the response to any GH-axis protocol is shaped by a second endocrine system that rarely gets discussed at the consultation stage: the thyroid. Thyroid hormone sets the metabolic tempo of almost every tissue in the body, and it directly influences how much growth hormone the pituitary releases, how much IGF-1 the liver produces in response, and how sensitive peripheral tissues are to both. An undiagnosed or under-treated thyroid imbalance is one of the most common reasons a well-designed peptide protocol underperforms.

How thyroid hormone and growth hormone interact

The two axes are wired together at several levels. In the pituitary, thyroid hormone (T3) is required for normal expression of the growth hormone gene, and animal and human data both show that hypothyroidism reduces spontaneous GH pulse amplitude and the GH response to secretagogue stimulation. Downstream, the liver needs adequate T3 to convert a GH signal into IGF-1, the mediator responsible for most of the anabolic and repair effects patients are seeking. Clinical studies in hypothyroid adults consistently report low IGF-1 levels that normalise once thyroid replacement is established, without any change in GH dosing.

The relationship runs in the other direction as well. Growth hormone and IGF-1 increase the peripheral conversion of T4 to the active T3 form, which means that starting a GH-axis peptide can subtly shift thyroid status. In someone with a healthy gland this is a minor, self-correcting effect. In someone with borderline thyroid reserve or on a fixed dose of levothyroxine, research suggests it can unmask or worsen an existing imbalance and occasionally requires a dose adjustment.

Thyroid hormone is the permissive signal that lets a GH-axis peptide do its job. Without it, the pituitary releases less, the liver responds less, and the tissues listen less.

What a thyroid panel should include before a protocol

A single TSH reading is a screening test, not a full picture. TSH can sit within the reference range while free T3 is at the bottom of the range and reverse T3 is elevated, a pattern often seen in people who are under chronic stress, restricting calories or training hard in the Gulf heat. Because peptide therapy is typically prescribed to exactly this population, our clinical team asks for a broader panel before any GH-axis protocol begins.

Reading these together allows a prescriber to distinguish three very different situations: a healthy thyroid that needs no intervention, an overt hypothyroid state that must be treated before a peptide protocol makes sense, and a subclinical or conversion-related pattern where lifestyle, nutrition and sometimes medication are addressed in parallel with the peptide plan.

Sequencing: thyroid first, then the GH axis

When the panel shows an overt imbalance, the clinical answer is almost always to correct the thyroid before layering a secretagogue on top. Starting ipamorelin or CJC-1295 in an untreated hypothyroid patient tends to produce a disappointing IGF-1 response, and it is easy to conclude that the peptide has not worked when the real limiting factor was upstream. Conversely, an overactive thyroid combined with a GH-axis peptide can amplify heart rate, heat intolerance and sleep disruption, which matters in a climate where those symptoms are already common. Once thyroid status is stable for several weeks, the peptide protocol is introduced and IGF-1 is rechecked at the usual six-to-eight-week review.

Clinical nuance: patients already on levothyroxine

Patients with established hypothyroidism on replacement therapy are not excluded from peptide protocols, but they are monitored more closely. Because GH and IGF-1 increase T4-to-T3 conversion, free T3 may drift upward after a secretagogue is started while TSH drifts down. This is usually modest and requires no action, but a repeat thyroid panel at the first review is standard practice, and any dose change to levothyroxine is coordinated with the patient's endocrinologist or GP rather than made in isolation. Timing also matters: levothyroxine is best taken on an empty stomach, and subcutaneous peptides do not interfere with its absorption, but patients are advised to keep the two on a consistent daily schedule so that blood results are comparable from one review to the next.

The broader principle is that peptide therapy is one input into an integrated endocrine system rather than a standalone intervention. The thyroid is the clearest example of a background hormone that quietly determines whether a protocol delivers, and it is one of the reasons physician-led prescribing under DHA licensing includes a full blood panel rather than a symptom questionnaire.

If you're exploring GH-axis peptides and want to understand how your thyroid status fits into the picture, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.